The R&D pipeline for depression therapies faced a demoralizing 2025 as five high-profile candidates, including KOR ...

Genetic differences in early- and late-onset depression highlight distinct risk profiles, informing targeted strategies for improved clinical outcomes.

The leading Major Depressive Disorder Companies such as GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, ...

The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...

The largest and most ethnically diverse study of its kind has identified 697 genetic variants linked to major depressive disorder (MDD). The research also highlights potential therapies for ...

Intra-Cellular Therapies’ surging antipsychotic Caplyta has scored again with remarkable trial results, fueling its bid for a third and potentially most lucrative indication—major depressive disorder ...

Adding lumateperone (Caplyta; Johnson & Johnson) to ongoing antidepressant therapy (ADT) significantly improved depression severity in adults with major depressive disorder (MDD) who had not responded ...

Neuropsychiatric drug development is rife with clinical trial failures, but Alto Neuroscience aims to overcome these hurdles with a precision medicine approach that matches a patient to a drug. A ...

Please provide your email address to receive an email when new articles are posted on . The clearance was based on a study in which adults with MDD used Rejoyn or a sham treatment app for 6 weeks. One ...

Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved ...